[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Michele van Vugt\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100615853",false,"NCT07298005","Sonlicromanol in Post-COVID","SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial","SON4PEM","Inclusion Criteria:\n\n* Post COVID according to WHO criteria and verified by post COVID physician\n* Post-exertional malaise (PEM) according to DSQ-PEM questionnaire\n* Bell's disability score 20-70%\n* Mild initial SARS-CoV-2 infection (no hospitalisation)\n* WHO performance score of 0 before initial SARS-CoV-2 infection\n\nExclusion Criteria:\n\n* Patients at risk for cardiac conduction disorders\n* History of clinical significant gastro-intestinal surgery or dysmotility that impairs the adsorption of the IMP\n* Clinically significant respiratory or cardiovascular disease\n* Unstable neurological disease\n* Clinically significant active psychiatric disorder that requires treatment\n* History of substance abuse\n* Active malignancy within the past 5 years\n* History of solid organ transplantation\n* Active HIV, hepatitis B or C infection\n* BMI \\\u003C 18.5 or \\> 35\n* Pregnancy or breastfeeding\n* Clinically relevant laboratory test value outside the reference range\n* Use of the following medication, unless stable for at least one month before study and remaining stable throughout the study: (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, amino acids, antioxidant supplements and any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, antivirals, amiodarone and NSAIDs)\n* Use of the following medication: any moderate or strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', HIV antivirals, grapefruit), strong CYP3A4 inducers ((including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort, pioglitazone, troglitazone) or any medication metabolized by CYP3A4 with a narrow therapeutic index, medication known to be substrate of Organic Cation Transporter 1 (OCT1) and organic cation transporter 2 (OCT2) or strong P-glycoprotein inhibitors (including amiodarone, azithromycin, captopril, clarithromycin, cyclosporine, piperine, quercetin, quinidine, quinine, reserpine, ritonavir, tariquidar, and verapamil).\n* Use of any medication known to affect cardiac repolarization unless QTc interval at screening is normal during stable treatment for a period of two weeks, or 5 half-lives","ALL","18 Years","65 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).",[27],"Post COVID Condition","RECRUITING","2026-04-07",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":21},"2026-04",{"date":36,"type":21},"2027-03",{"name":38,"class":39},"Michele van Vugt","OTHER",""]